Light Sensitization Study

June 29, 2021 updated by: Jeanne Duffy, Brigham and Women's Hospital

Sensitization of Human Circadian Responses to Light

Circadian rhythm disorders are a class of sleep disorders characterized by misalignment between the timing of sleep and the timing of rhythms driven by the biological clock. Light therapy can effectively treat these disorders, but the intensity and duration of light exposure required to do so has limited its practical use. In this study the investigators will test whether pre-exposure to dim light may enhance the response of the circadian system to light therapy. If so, this could result in shorter treatments that would have greater practical applications.

Study Overview

Detailed Description

Sleep disorders affect 35-40% of adults, resulting in diminished quality of life, and increased morbidity, mortality, and risk of automobile and occupational accidents. Circadian rhythm sleep disorders form a distinct class of sleep disorders characterized by misalignment between the timing of sleep and the circadian pacemaker. While light therapy can be an effective treatment of circadian rhythm sleep disorders, there are numerous practical limitations.

Light is the most powerful signal from the environment that influences and regulates daily biological rhythms. It is well-established that the irradiance, duration, and timing of light exposure all affect the response of the circadian system. While it was once thought that these responses were mediated through the visual system, it is now known that there is a network of intrinsically photosensitive retinal ganglion cells (ipRGCs) that mediate circadian responses to light. Other new studies have demonstrated that recent light exposure history affects the circadian response to light in humans.

These recent findings have important implications for the use of light to treat circadian rhythm disorders, including delayed and advanced sleep phase disorders, shift work sleep disorder, and jet lag, and they may also have relevance for the use of light to treat seasonal affective disorder. Up to now, little attention has been paid to the duration or intensity of light exposure prior to such light treatments. The investigators now have evidence that the human circadian system can become desensitized to light during long exposures and evidence that it can be sensitized to light by prior exposure to dim light. These recent findings suggest that light treatment protocols that sensitize the circadian system prior to the light treatment will be more effective than those currently in use.

The 13-day inpatient studies the investigators propose will examine the effect on the human circadian system of different durations of dim-light sensitization prior to a standardized light treatment. These results will be compared within subjects in a randomized cross-over design study in which each subject will receive a control treatment and a light treatment with prior dim-light sensitization. The investigators will also include circadian phase disorder patients to test these mechanisms in the target patient population. Our findings will provide an important step in understanding how new knowledge about the circadian photoreceptive system can be used to refine and provide better treatment options for circadian rhythm disorders.

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02115
        • Brigham and Women's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

17 years to 26 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • healthy adults with conventional and regular sleep-wake timing
  • non-smokers
  • completion of medical, psychological, ophthalmological, and sleep screening tests
  • able to spend 13 consecutive days/nights in the laboratory

Exclusion Criteria:

  • history of neurological or psychiatric disorder
  • history of eye injury, eye surgery, or visual disorder (corrective lenses are acceptable)
  • history of sleep disorder or regular use of sleep-promoting medication
  • current prescription, herbal, or over-the-counter medication use (oral contraceptives are acceptable)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: sensitization duration 1.375h
This group will experience a 1.375h sensitization duration prior to the 12h light exposure
12-hour light exposure of approximately 200 lux
Experimental: sensitization duration 5.5h
This group will experience a 5.5h sensitization duration prior to the 12h light exposure
12-hour light exposure of approximately 200 lux
Experimental: sensitization duration 22h
This group will experience a 22h sensitization duration prior to the 12h light exposure
12-hour light exposure of approximately 200 lux
Experimental: sensitization duration 0.33h
This group will experience a 0.33h sensitization duration prior to the 12h light exposure
12-hour light exposure of approximately 200 lux

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
circadian phase timing
Time Frame: During inpatient study, on days 6-7 and 11-12
timing of circadian phase as assessed using melatonin and temperature data
During inpatient study, on days 6-7 and 11-12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
melatonin suppression
Time Frame: During inpatient study, on days 6-7 and 11-12
percent of melatonin suppression
During inpatient study, on days 6-7 and 11-12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Jeanne F Duffy, PhD, Brigham and Women's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2010

Primary Completion (Actual)

December 1, 2015

Study Completion (Actual)

December 1, 2020

Study Registration Dates

First Submitted

March 30, 2011

First Submitted That Met QC Criteria

March 30, 2011

First Posted (Estimate)

April 1, 2011

Study Record Updates

Last Update Posted (Actual)

July 1, 2021

Last Update Submitted That Met QC Criteria

June 29, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sleep Disorders, Circadian Rhythm

Clinical Trials on light exposure

Subscribe